// App-Quantinova.ai

: Ropeginterferon Alfa-2b Versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Final Results of Low-PV Randomized Phase II Trial

Researchers

Presenter

  • Tiziano Barbui

Principal Investigators

  • Valerio De Stefano

  • Arianna Masciulli

  • Alessandra Carobbio

  • Arianna Ghirardi

  • Greta Carioli

  • Elena Rossi

  • Fabio Ciceri

  • Massimiliano Bonifacio

  • Alessandra Iurlo

  • Francesca Palandri

  • Giulia Benevolo

  • Fabrizio Pane

  • Alessandra Ricco

  • Giuseppe Carli

  • Marianna Caramella

  • Davide Rapezzi

  • Caterina Musolino

  • Sergio Siragusa

  • Elisa Rumi

  • Andrea Patriarca

  • Nicola Cascavilla

  • Barbara Mora

  • Emma Cacciola

  • Carmela Mannarelli

  • Giuseppe Gaetano Loscocco

  • Paola Guglielmelli

  • Francesca Gesullo

  • Silvia Betti

  • Francesca Lunghi

  • Luigi Scaffidi

  • Cristina Bucelli

  • Nicola Vianelli

  • Marta Bellini

  • Maria Chiara Finazzi

  • Giovanni Tognoni

  • Alessandro Rambaldi

Medical Centers

  • CRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, University of Florence, AOU Careggi, Florence, Italy;, Florence, Italy

  • Department of Medicine, Section of Hematology, University of Verona and Azienda Ospedaliera Universitaria Integrata, Verona, Italy

  • CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, University of Florence, Florence, Italy

  • Università degli Studi di Napoli, Federico II, Italy

  • Department of Onco-Haematology - Haematology and Bone Marrow Transplantation, IRCCS San Raffaele Scientific Institute and Vita-Salute Hospital, Milano, Italy

  • Department of Oncology-Hematology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy

  • Hematology Division, Città della Salute e della Scienza Hospital, TORINO, Italy

  • FROM Research Foundation Ospedale di Bergamo, Bergamo, Italy

  • Department of Molecular Medicine, University of Pavia, Pavia, Italy

  • Università Vita-Salute San Raffaele and Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele, Department of Onco-Hematology, Milano, Italy

  • Hematology and Stem Cell Transplantation Unit, AOUC Policlinico, Bari, Italy

  • Divisione di Ematologia - Policlinico Universitario, Messina, Italy

  • Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico A Gemelli, IRCCS, Rome, Italy

  • S.C. Ematologia, ASO S. Croce e Carle, Cuneo, Italy

  • Hematology Department, Ospedale San Bortolo, Vicenza, Italy

  • Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy

  • Azienda Ospedaliero Universitaria Maggiore della Carità di Novara SCDU Ematologia, Novara, Italy

  • Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy

  • Department of Oncology and Hematology, University of Milan, Milan, Italy

  • Azienda Ospedaliera Universitaria Federico II, Naples, Italy

  • Hematology and Bone Marrow Transplant Unit, ASST Papa Giovanni XXIII, Bergamo, Italy

  • Division of Hematology, IRCCS Casa Sollievo Della Sofferenza Hospital, San Giovanni Rotondo, Italy

  • Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

  • Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PRO.MI.SE), University of Palermo, Palermo, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Polycythemia vera

  • Venous thrombosis

Biomarkers

  • Hematocrit

Drug/Treatment

  • Ropeginterferonum alfa 2b

Outcome

  • N/A

Study Design

  • Randomized

  • Safety

  • Fixed Dose

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved